English

Amphastar Pharmaceuticals, Inc.

EDGAR

AMPH Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 719.9M, using the latest reported figures. The previous period, 2024, was about Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 732M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

184 million Unit_Standard_USD_nUTgKG4CHEyKSOYOeHgfaQ

2026 Q2 · Unit_Standard_USD_nUTgKG4CHEyKSOYOeHgfaQ

Exact inputs and evidence

Revenue: 183903000 Unit_Standard_USD_nUTgKG4CHEyKSOYOeHgfaQ Source

Operating margin

21.6%

2026 Q2 · %

Exact inputs and evidence

Operating Income: 39729000 Unit_Standard_USD_nUTgKG4CHEyKSOYOeHgfaQ Source
Revenue: 183903000 Unit_Standard_USD_nUTgKG4CHEyKSOYOeHgfaQ Source

Cash and cash equivalents: 224 million Unit_Standard_USD_nUTgKG4CHEyKSOYOeHgfaQ 2026-06-30 Source
Exact value

223614000 Unit_Standard_USD_nUTgKG4CHEyKSOYOeHgfaQ
Long-term debt including current maturities: 40.3 million Unit1 2015-12-31 Source
Exact value

40295000 Unit1
Shares outstanding: 42.5 million Unit_Standard_shares_SOQ_TNnUvUW2jXGRckq8pA 2026-06-30 Source
Exact value

42532225 Unit_Standard_shares_SOQ_TNnUvUW2jXGRckq8pA

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2015-12-31
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-1.7%

Prior period

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 731.97 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 719.89 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

719887000 − 731967000 = -12080000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew

731967000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
719887000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Amphastar Pharmaceuticals, Inc. · 2025-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Year-over-year change in Revenue: -12080000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 719887000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2574640 Filing: 000129718426000009 Input fundies:Revenue: 731967000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2575652 Filing: 000129718426000009
The citation records this snapshot. The page link may show a newer release later.
Net income
-38.5%

Prior period

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 159.52 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 98.09 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

98094000 − 159519000 = -61425000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew

159519000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
98094000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Amphastar Pharmaceuticals, Inc. · 2025-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Year-over-year change in Net income: -61425000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 98094000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2400335 Filing: 000129718426000009 Input fundies:NetIncome: 159519000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2401285 Filing: 000129718426000009
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-26.8%

Prior period

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 213.39 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 156.12 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

156115000 − 213386000 = -57271000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew

213386000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
156115000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Amphastar Pharmaceuticals, Inc. · 2025-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Year-over-year change in Operating cash flow: -57271000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 156115000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2092908 Filing: 000129718426000009 Input fundies:OperatingCashFlow: 213386000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2094065 Filing: 000129718426000009
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-15%

Prior period

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 41.04 million

2024-01-01 – 2024-12-31
Current period

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 34.88 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

34882000 − 41041000 = -6159000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew

41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Amphastar Pharmaceuticals, Inc. · 2025-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Year-over-year change in Capital expenditure: -6159000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2105531 Filing: 000129718426000009 Input fundies:CapitalExpenditure: 41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2106613 Filing: 000129718426000009
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 719.89 million 100% of revenue
Cost of revenue Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 363.83 million 51% of revenue
Operating expenses Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 215.65 million 30% of revenue
Operating income Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 140.4 million 20% of revenue
Tax, interest and other Derived Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 42.31 million 5.9% of revenue
Net income Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 98.09 million 14% of revenue

Cash

Operating cash flow Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 156.12 million 22% of revenue
Capital expenditure Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 34.88 million 4.8% of revenue
Free cash flow Derived Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 121.23 million 17% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 21%9.2%69%
2024 22%72%
2025 14%80%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	644395000	447408000 Derived	196987000	59442000 Derived	137545000	145337000 Derived	Source 2023-01-01 – 2023-12-31: 644395000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Revenue Open source 2023-01-01 – 2023-12-31: 196987000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 137545000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Net Income Open source 2023-01-01 – 2023-12-31: 183503000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 38166000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	731967000	526548000 Derived	205419000	45900000 Derived	159519000	172345000 Derived	Source 2024-01-01 – 2024-12-31: 731967000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Revenue Open source 2024-01-01 – 2024-12-31: 205419000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Operating Income Open source 2024-01-01 – 2024-12-31: 159519000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Net Income Open source 2024-01-01 – 2024-12-31: 213386000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	719887000	579484000 Derived	140403000	42309000 Derived	98094000	121233000 Derived	Source 2025-01-01 – 2025-12-31: 719887000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Revenue Open source 2025-01-01 – 2025-12-31: 140403000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Operating Income Open source 2025-01-01 – 2025-12-31: 98094000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Net Income Open source 2025-01-01 – 2025-12-31: 156115000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Capital Expenditure Open source

Amounts are exact, in Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 719.9M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew)	Source evidence
20232023-12-31	Revenue	644395000	Revenue: 644395000 Open source
20242024-12-31	Revenue	731967000	Revenue: 731967000 Open source
20252025-12-31	Revenue	719887000	Revenue: 719887000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-1.7% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 644395000 Open source
20242024-12-31	Year over year	13.6%	Revenue: 731967000 Open source Revenue: 644395000 Open source
20252025-12-31	Year over year	-1.7%	Revenue: 719887000 Open source Revenue: 731967000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 19.5% 2025

Net margin 13.6% 2025

Free cash flow margin 16.8% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	30.6%	Operating Income: 196987000 Open source Revenue: 644395000 Open source
20242024-12-31	Operating margin	28.1%	Operating Income: 205419000 Open source Revenue: 731967000 Open source
20252025-12-31	Operating margin	19.5%	Operating Income: 140403000 Open source Revenue: 719887000 Open source
20232023-12-31	Net margin	21.3%	Net Income: 137545000 Open source Revenue: 644395000 Open source
20242024-12-31	Net margin	21.8%	Net Income: 159519000 Open source Revenue: 731967000 Open source
20252025-12-31	Net margin	13.6%	Net Income: 98094000 Open source Revenue: 719887000 Open source
20232023-12-31	Free cash flow margin	22.6%	Revenue: 644395000 Open source Operating Cash Flow: 183503000 Open source Capital Expenditure: 38166000 Open source
20242024-12-31	Free cash flow margin	23.5%	Revenue: 731967000 Open source Operating Cash Flow: 213386000 Open source Capital Expenditure: 41041000 Open source
20252025-12-31	Free cash flow margin	16.8%	Revenue: 719887000 Open source Operating Cash Flow: 156115000 Open source Capital Expenditure: 34882000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 156.1M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew)	Source evidence
20232023-12-31	Operating cash flow	183503000	Operating Cash Flow: 183503000 Open source
20242024-12-31	Operating cash flow	213386000	Operating Cash Flow: 213386000 Open source
20252025-12-31	Operating cash flow	156115000	Operating Cash Flow: 156115000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 121.2M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew)	Source evidence
20232023-12-31	Free cash flow	145337000	Operating Cash Flow: 183503000 Open source Capital Expenditure: 38166000 Open source
20242024-12-31	Free cash flow	172345000	Operating Cash Flow: 213386000 Open source Capital Expenditure: 41041000 Open source
20252025-12-31	Free cash flow	121233000	Operating Cash Flow: 156115000 Open source Capital Expenditure: 34882000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Liabilities / assets	Not reported	No source recorded
2024-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2024-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 137.55 million Exact value Exact value: 137545000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2023-01-01 – 2023-12-31: 137545000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Net Income Open source Share or cite Citation for Net Income · Amphastar Pharmaceuticals, Inc. · 2023-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Net Income: 137545000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew&dimensions= Input fundies:NetIncome: 137545000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2402236 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 183.5 million Exact value Exact value: 183503000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2023-01-01 – 2023-12-31: 183503000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Amphastar Pharmaceuticals, Inc. · 2023-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Operating Cash Flow: 183503000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew&dimensions= Input fundies:OperatingCashFlow: 183503000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2095222 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 38.17 million Exact value Exact value: 38166000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2023-01-01 – 2023-12-31: 38166000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Amphastar Pharmaceuticals, Inc. · 2023-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Capital Expenditure: 38166000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew&dimensions= Input fundies:CapitalExpenditure: 38166000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2107695 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 145.34 million Calculation and evidence 183503000 − 38166000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Exact free cash flow: 145337000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2023-01-01 – 2023-12-31: 183503000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 38166000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Amphastar Pharmaceuticals, Inc. · 2023-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Free cash flow: 145337000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 183503000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2095222 Filing: 000129718426000009 Input fundies:CapitalExpenditure: 38166000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2107695 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 159.52 million Exact value Exact value: 159519000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2024-01-01 – 2024-12-31: 159519000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Net Income Open source Share or cite Citation for Net Income · Amphastar Pharmaceuticals, Inc. · 2024-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Net Income: 159519000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew&dimensions= Input fundies:NetIncome: 159519000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2401285 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 213.39 million Exact value Exact value: 213386000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2024-01-01 – 2024-12-31: 213386000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Amphastar Pharmaceuticals, Inc. · 2024-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Operating Cash Flow: 213386000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew&dimensions= Input fundies:OperatingCashFlow: 213386000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2094065 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 41.04 million Exact value Exact value: 41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2024-01-01 – 2024-12-31: 41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Amphastar Pharmaceuticals, Inc. · 2024-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Capital Expenditure: 41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew&dimensions= Input fundies:CapitalExpenditure: 41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2106613 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 172.35 million Calculation and evidence 213386000 − 41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Exact free cash flow: 172345000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2024-01-01 – 2024-12-31: 213386000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Amphastar Pharmaceuticals, Inc. · 2024-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Free cash flow: 172345000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 213386000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2094065 Filing: 000129718426000009 Input fundies:CapitalExpenditure: 41041000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2106613 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 98.09 million Exact value Exact value: 98094000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2025-01-01 – 2025-12-31: 98094000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Net Income Open source Share or cite Citation for Net Income · Amphastar Pharmaceuticals, Inc. · 2025-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Net Income: 98094000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew&dimensions= Input fundies:NetIncome: 98094000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2400335 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 156.12 million Exact value Exact value: 156115000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2025-01-01 – 2025-12-31: 156115000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Amphastar Pharmaceuticals, Inc. · 2025-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Operating Cash Flow: 156115000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew&dimensions= Input fundies:OperatingCashFlow: 156115000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2092908 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 34.88 million Exact value Exact value: 34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2025-01-01 – 2025-12-31: 34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Amphastar Pharmaceuticals, Inc. · 2025-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Capital Expenditure: 34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew&dimensions= Input fundies:CapitalExpenditure: 34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2105531 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 121.23 million Calculation and evidence 156115000 − 34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Exact free cash flow: 121233000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew 2025-01-01 – 2025-12-31: 156115000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Amphastar Pharmaceuticals, Inc. · 2025-12-31 Amphastar Pharmaceuticals, Inc. (edgar:1297184) Free cash flow: 121233000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:29:08Z Snapshot: ce48dea60ad627533905bc14179a5daf37ed7a8e2fdbe97683c20671837ddee0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1297184?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 156115000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2092908 Filing: 000129718426000009 Input fundies:CapitalExpenditure: 34882000 Unit_Standard_USD_EPj2TWUds0qIZ9qMADn5Ew (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000009/amph-20251231x10k.htm#2105531 Filing: 000129718426000009 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

204 filings · 11,812 latest values · 11,812 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001297184, 1297184, AMPH, amph, edgar:1297184

Also known as Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation